title: Arsenic trioxide inhibits ATRA-induced prostaglandin E2 and cyclooxygenase-1 in NB4 cells, a model of acute promyelocytic leukemia.
abstract: In acute promyelocytic leukemia (APL), all-trans retinoic acid (ATRA) triggers cell differentiation, while arsenic trioxide (As(2)O(3)) generates partial differentiation and apoptosis. Animal and human studies suggest that newly diagnosed APL patients can be cured using As(2)O(3) combined with ATRA. Cyclooxygenases are involved in prostaglandins and thromboxane synthesis. We have recently demonstrated that ATRA induces cyclooxygenase-1 (COX-1) expression and prostaglandin synthesis in NB4 cells and in blasts from patients with APL. In the present study we investigated the effect of ATRA and As(2)O(3) co-treatment on COX-1 expression and prostaglandin formation and tested the effect of the COX-1/COX-2 nonselective inhibitor indomethacin on cell differentiation. Arsenic treatment of NB4 cells resulted in a partial but significant reduction of ATRA-dependent induction of COX-1 expression and activity. Pretreatment of NB4 cells with indomethacin significantly impaired ATRA/As(2)O(3)-induced differentiation, as assessed by cell morphology, nitroblue tetrazolium test or CD11c expression. PGE(2) reversed the negative effect of indomethacin on differentiation of ATRA/As(2)O(3)-treated NB4 cells. In conclusion, COX-1 contributes to ATRA-dependent maturation of NB4 cells and is affected by As(2)O(3). These results also suggest that nonsteroidal antiinflammatory drugs should be avoided in APL patients treated with the combination of ATRA and As(2)O(3).
authors: Department of Biochemistry, American University of Beirut, Beirut, Lebanon. ah31@aub.edu.lb
authors: A
authors: A
authors: Habib
authors: E
authors: E
authors: Hamade
authors: R
authors: R
authors: Mahfouz
authors: M S
authors: MS
authors: Nasrallah
authors: H
authors: H
authors: de Thé
authors: A
authors: A
authors: Bazarbachi
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000494:pharmacology*; D015153:Blotting, Western; D039521:CD11c Antigen / Q000378:metabolism; D002454:Cell Differentiation; D051545:Cyclooxygenase 1 / Q000378:metabolism*; D015232:Dinoprostone / Q000378:metabolism*; D004359:Drug Therapy, Combination; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008954:Models, Biological; D010087:Oxides / Q000494:pharmacology*; D014212:Tretinoin / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents; D001152:Arsenicals; D039521:CD11c Antigen; D010087:Oxides; D014212:Tretinoin; D051545:Cyclooxygenase 1; D015232:Dinoprostone; D000077237:Arsenic Trioxide; D007213:Indomethacin